The allure of achieving incredible gains in short time periods has many investors looking to strike it rich picking biotech stocks. But it's also attracted the attention of many fund companies, which are looking to capitalize on the average investor's interest in a more diversified form of biotech exposure. While my personal preference for the longer-term investor looking to invest in biotech is to target a basket of stocks, in the following video, I offer up an opinion on the biotech ETF that best captures the essence of biotech investing.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Better Way to Play Biotech
NYSEMKT: XBI
SPDR Series Trust - SPDR S&P Biotech ETF

If you're going the ETF route, this product appears to be the best option
Brenton Flynn owns shares of Sarepta Therapeutics. The Motley Fool owns shares of Dendreon. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.